Salvage chemotherapy for hormone-refractory prostate cancer: Association of Adriamycin and ifosfamide

Abstract

Prostate carcinoma is the most common cancer in men. Hormone-resistance is the natural history of this metastatic disease and requires the use of docetaxel as the standard chemotherapy. At present, there is no approved second-line treatment. Here, we report a combination of treatment with Adriamycin and ifosfamide in a series of 7 relatively young patients with an average age of 57 years at the time of diagnosis. Chemotherapy was administered over 3 days with the following schedule: 20 mg/m(2) Adriamycin per day and 1-1.5 mg/m(2) ifosfamide per day, in association with Uromitexan. Treatment was repeated every 3 weeks. Three biological responses, one CT scan response, one bone scan response and two CT scan stabilizations, were obtained. Mean survival following this combination was 6.6 months, and over 26 months after first-line chemotherapy. Tolerance was good with the use of granulocyte-colony stimulating factors. Our observations clearly show that the use of this type of salvage therapy for relatively young patients in good physical condition should be further assessed in a clinical trial, particularly when different lines of chemotherapy are required.